A heart transplant, or a cardiac transplant, is a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease. As of 2008 the most common procedure is to take a working heart from a recently deceased organ donor (cadaveric allograft) and implant it into the patient. The patient’s own heart is either removed (orthotopic procedure) or, less commonly, left in place to support the donor heart (heterotopic procedure). Post-operation survival periods average 15 years. Heart transplantation is not considered to be a cure for heart disease, but a life-saving treatment intended to improve the quality of life for recipients. One of the important measure for managing patients post surgery is the reaction of the immune system to the transplanted heart (organ rejection).  Current methods require some lab test, or biopsies.  The latter is dangerous.  Using Myocardial Solutions’ products, many measurements of change in the tissue of the heart can help determine whether a rejection process is occurring and its extent.  One of these indicators is the changes in contractility as measured by strain.

Relevant Papers

Wu YL, Ye Q, Eytan DF, Liu L, Rosario BL, Hitchens TK, Yeh F-C and Ho C. Magnetic Resonance Imaging Investigation of Macrophages in Acute Cardiac Allograft Rejection After Heart TransplantationCirculation: Cardiovascular Imaging. 2013;6:965–973.

Wu YL, Ye Q, Sato K, Foley LM, Hitchens TK and Ho C. Noninvasive evaluation of cardiac allograft rejection by cellular and functional cardiac magnetic resonance. JACC: Cardiovascular Imaging. 2009;2:731–741.

Korosoglou G, Osman NF, Dengler TJ, Riedle N, Steen H, Lehrke S, Giannitsis E and Katus HA. Strain-encoded cardiac magnetic resonance for the evaluation of chronic allograft vasculopathy in transplant recipientsAm J Transplant. 2009;9:2587-96.

Wu YL, Ye Q, Sato K, Foley LM, Hitchens TK and Ho C. Non-invasive monitoring allograft rejection by simultaneous cellular and functional cardiac MRI. Journal of Cardiovascular Magnetic Resonance. 2009;11:O79.

Korosoglou G, Riedle N, Erbacher M, Dengler TJ, Zugck C, Rottbauer W, Hardt S, Bekeredjian R, Kristen A, Giannitsis E, Osman NF, Dickhaus H and Katus HA. Quantitative myocardial blush grade for the detection of cardiac allograft vasculopathy. Am Heart J. 2010;159:643-651 e2.

Contact Us

We work with Medical Research Centers, MRI Manufacturers,
Outpatient Imaging Centers and Physicians

Myocardial Solutions' technology has been used globally in over 70 major medical research centers and is established as the gold standard for strain measurement. The research has yielded over 250 articles in peer-reviewed journals (50 articles from Circulation and JACC alone) that validate CMR strain testing. MyoStrain’s predecessor software (HARP & VIRTUE) have 510(k) clearance and CE Mark certification.
MyoStrain has CE mark certification, and Myocardial Solutions is actively pursuing FDA 510(k) clearance for MyoStrain.